Middle East & Africa Oncology Clinical Trials Market Size & Outlook

The oncology clinical trials market in Middle East & Africa is expected to reach a projected revenue of US$ 256.8 million by 2030. A compound annual growth rate of 5.5% is expected of Middle East & Africa oncology clinical trials market from 2024 to 2030.
Revenue, 2023 (US$M)
$176.1
Forecast, 2030 (US$M)
$256.8
CAGR, 2024 - 2030
5.5%
Report Coverage
Middle East & Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa oncology clinical trials market, 2018-2030 (US$M)

Middle East & Africa oncology clinical trials market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

MEA oncology clinical trials market highlights

  • The MEA oncology clinical trials market generated a revenue of USD 176.1 million in 2023.
  • The market is expected to grow at a CAGR of 5.5% from 2024 to 2030.
  • In terms of segment, phase iii was the largest revenue generating phase in 2023.
  • Phase II is the most lucrative phase segment registering the fastest growth during the forecast period.
  • Country-wise, Kuwait is expected to register the highest CAGR from 2024 to 2030.

MEA data book summary

Market revenue in 2023USD 176.1 million
Market revenue in 2030USD 256.8 million
Growth rate5.5% (CAGR from 2023 to 2030)
Largest segmentPhase iii
Fastest growing segmentPhase II
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwideAstraZeneca PLC, Merck KGaA, IQVIA Holdings Inc, Gilead Sciences Inc, Roche Holding AG, PAREXEL, Icon PLC, Syneos Health, Medpace Holdings Inc, Novotech, Broadcom Inc

Other key industry trends

  • In terms of revenue, MEA region accounted for 1.3% of the global oncology clinical trials market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 4,258.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Oncology Clinical Trials Market Companies

Name Profile # Employees HQ Website
Novotech View profile 1001-5000 Sydney, New South Wales, Australia, Oceania http://www.novotech-cro.com/
Syneos Health View profile 1001-5000 Morrisville, North Carolina, United States, North America https://www.syneoshealth.com/
PAREXEL View profile 10001+ Waltham, Massachusetts, United States, North America http://www.parexel.com
IQVIA Holdings Inc View profile 87000 2400 Ellis Road, Durham, NC, United States, 27703 https://www.iqvia.com
Gilead Sciences Inc View profile 18000 333 Lakeside Drive, Foster, CA, United States, 94404 https://www.gilead.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Medpace Holdings Inc View profile 5800 5375 Medpace Way, Cincinnati, OH, United States, 45227 https://www.medpace.com
Icon PLC View profile 41150 South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 https://www.iconplc.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Broadcom Inc View profile 20000 3421 Hillview Avenue, Palo Alto, CA, United States, 94304 https://www.broadcom.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

Middle East & Africa oncology clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology clinical trials market will help companies and investors design strategic landscapes.


Phase iii was the largest segment with a revenue share of 62.63% in 2023. Horizon Databook has segmented the Middle East & Africa oncology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


  • Middle East & Africa Oncology Clinical Trials Phase Outlook (Revenue, USD Million, 2018-2030)
    • Phase IV
    • Others
    • Phase II
    • Phase I
    • Phase III
  • Middle East & Africa Oncology Clinical Trials Study Design Outlook (Revenue, USD Million, 2018-2030)
    • Interventional trials
    • Expanded access trials
    • Observational trials

Reasons to subscribe to Middle East & Africa oncology clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa oncology clinical trials market databook

  • Our clientele includes a mix of oncology clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa oncology clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa oncology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA oncology clinical trials market size, by country, 2018-2030 (US$M)

Middle East & Africa Oncology Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

MEA oncology clinical trials market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online